Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Mallinckrodt
Johnson and Johnson
Medtronic
Express Scripts

Last Updated: January 24, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Omaveloxolone


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Omaveloxolone?

Omaveloxolone is an investigational drug.

There have been 10 clinical trials for Omaveloxolone. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.

The most common disease conditions in clinical trials are Melanoma, Mitochondrial Myopathies, and Lung Neoplasms. The leading clinical trial sponsors are Reata Pharmaceuticals, Inc., AbbVie, and Friedreich's Ataxia Research Alliance.

There are fifteen US patents protecting this investigational drug and two hundred and thirty-nine international patents.

Recent Clinical Trials for Omaveloxolone
TitleSponsorPhase
A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic FunctionReata Pharmaceuticals, Inc.Phase 1
A Clinical Drug-Drug Interaction (DDI) Study With OmaveloxoloneCovancePhase 1
A Clinical Drug-Drug Interaction (DDI) Study With OmaveloxoloneReata Pharmaceuticals, Inc.Phase 1

See all Omaveloxolone clinical trials

Clinical Trial Summary for Omaveloxolone

Top disease conditions for Omaveloxolone
Top clinical trial sponsors for Omaveloxolone

See all Omaveloxolone clinical trials

US Patents for Omaveloxolone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Omaveloxolone ⤷  Sign up for a Free Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign up for a Free Trial
Omaveloxolone ⤷  Sign up for a Free Trial Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) ⤷  Sign up for a Free Trial
Omaveloxolone ⤷  Sign up for a Free Trial Systems and methods for identifying cancer treatments from normalized biomarker scores BostonGene Corporation (Lincoln, MA) ⤷  Sign up for a Free Trial
Omaveloxolone ⤷  Sign up for a Free Trial Systems and methods for identifying cancer treatments from normalized biomarker scores BostonGene Corporation (Lincoln, MA) ⤷  Sign up for a Free Trial
Omaveloxolone ⤷  Sign up for a Free Trial Arylcyclohexyl pyrazoles as NRF2 regulators GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) Astex Therapeutics Limited (Cambridge, Cambridgeshire, GB) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Omaveloxolone

Drugname Country Document Number Estimated Expiration Related US Patent
Omaveloxolone Australia AU2017261372 2036-05-05 ⤷  Sign up for a Free Trial
Omaveloxolone Canada CA3023278 2036-05-05 ⤷  Sign up for a Free Trial
Omaveloxolone China CN107847398 2036-05-05 ⤷  Sign up for a Free Trial
Omaveloxolone European Patent Office EP3452003 2036-05-05 ⤷  Sign up for a Free Trial
Omaveloxolone Hong Kong HK1249728 2036-05-05 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Mallinckrodt
Johnson and Johnson
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.